Mitochondrial DNA Copy Number in Egyptian Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma
| Autor: | Perihan E. Salem, Doaa I. Hashad, Amany Elyamany |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Liver Cirrhosis Male medicine.medical_specialty Mitochondrial DNA Pathology Carcinoma Hepatocellular Cirrhosis DNA Copy Number Variations Hepatitis C virus Biology medicine.disease_cause DNA Mitochondrial Gastroenterology law.invention Liver disease Risk Factors law Internal medicine medicine Humans Genetics (clinical) Polymerase chain reaction Aged Liver Neoplasms Case-control study General Medicine Hepatitis C Middle Aged medicine.disease digestive system diseases ROC Curve Case-Control Studies Hepatocellular carcinoma Egypt Female |
| Zdroj: | Genetic Testing and Molecular Biomarkers. 19:604-609 |
| ISSN: | 1945-0257 1945-0265 |
| Popis: | To assess the use of mitochondrial DNA (mtDNA) content as a noninvasive molecular biomarker in hepatitis C virus-related hepatocellular carcinoma (HCV-HCC).A total of 135 participants were enrolled in the study. Equal numbers of subjects were enrolled in each of three clinically defined groups: those with HCV-related cirrhosis (HCV-cirrhosis), those with HCV-HCC, and a control group of age- and sex-matched healthy volunteers with no evidence of liver disease. mtDNA concentrations were determined using a quantitative real-time polymerase chain reaction (PCR) technique.mtDNA content was lowest among the HCV-HCC cases. No statistically significant difference was observed between the group of HCV-cirrhosis and the control group as regards mtDNA level. HCC patients with multicentric hepatic lesions had significantly lower mtDNA content than HCC patients with less advanced disease. When a receiver operating characteristic curve analysis was used, a cutoff of 34 was assigned for mtDNA content to distinguish between HCV-HCC and HCV-cirrhosis patients who are not yet complicated by malignancy. Lower mtDNA content was associated with HCC risk when using either or both healthy controls and HCV-cirrhosis groups for reference.mtDNA content analysis could serve as a noninvasive molecular biomarker that reflects tumor burden in HCV-HCC cases and could be used as a predictor of HCC risk in patients of HCV-cirrhosis. In addition, the nonsignificant difference of mtDNA level between HCV-cirrhosis patients and healthy controls could eliminate the gray zone created by the use of alpha-fetoprotein in some cirrhotic patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|